Targeted therapies of solid cancers: New options, new challenges

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 296-304

  Awada, Ahmad ^a   Aftimos, Philippe G ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

biomarkers; gene sequencing; heterogeneity; personalized cancer care; PET imaging; research biopsies

Indexed keywords

AFATINIB; AFLIBERCEPT; ASPARAGINASE; AXITINIB; BEVACIZUMAB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CABOZANTINIB; CARFILZOMIB; CETUXIMAB; CRIZOTINIB; ENZALUTAMIDE; ERLOTINIB; EVEROLIMUS; GEFITINIB; HOMOHARRINGTONINE; LAPATINIB; NERATINIB; PANITUMUMAB; PERTUZUMAB; PONATINIB; REGORAFENIB; RUXOLITINIB; SORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VEMURAFENIB; VINCRISTINE SULFATE; VISMODEGIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; DRUG APPROVAL; DRUG TOLERABILITY; GENE SEQUENCE; GENOMICS; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INVASIVE PROCEDURE; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOFIBROSIS; OVARY CANCER; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER; THYROID CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

BIOPSY; COMBINED MODALITY THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876297448     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff318     Document Type: Review

References (63)

1. Chapman PB, Hauschild A, Robert C, et al., BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
3. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1:44-53.
4. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383.
5. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979; 137:260-262.
6. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52:479-485.
7. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30:587-592.
8. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30:593-599.
9. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multicentre, multi-disciplinary prospective studies. Cancer Treat Rev 2012; 38:708-714.
10. Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 2010; 28:2635-2640.
11. El-Osta H, Hong D, Wheler J, et al. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist 2011; 16:1292-1298.
12. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-892.
13. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30:2956-2962.
14. Garraway LA. Concordance and discordance in tumor genomic profiling. J Clin Oncol 2012; 30:2937-2939.
15. Garraway LA, Baselga J. Whole-genome sequencing and cancer therapy: is too much ever enough? Cancer Discov 2012; 2:766-768.
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
17. Cancer Genome Project. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400-404.
18. Liang H, Cheung LW, Li J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endo-metrial cancer. Genome Res 2012; 22:2120-2129.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-615.
20. Cancer Genome Atlas Research Network; Hammerman PS, Hayes DN, Wilkerson MD, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-525.
21. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150:1107-1120.
22. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
23. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-103.
24. Behl AS, Goddard KA, Flottemesch TJ, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012; 104:1785-1795.
25. Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72:779-789.
26. Kantarjian H, Sawyers C, Hochhaus A, et al., International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
27. Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 2012; 18:6339-6347.
28. Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA 2012; 109:5299-5304.
29. Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013; 31:731-737.
30. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3:1-14.
31. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevaci-zumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29:11-16.
32. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307:1383-1393.
33. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizu-mab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-1260.
34. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bev-acizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29:4286-4293.
35. Cameron D, Brown J, Dent R, et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 2012; 72(24 Suppl):Abstract S6-5.
36. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534-1540.
37. Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012; 30:3012-3019.
38. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632-638.
39. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
40. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifiesabasis for everolimus sensitivity. Science 2012; 338:221.
41. Flaherty KT, Robert C, Hersey P, et al., METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-114.
42. Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012; 2:791-797.
43. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 2008; 20:206-219.
44. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012; 198:737-745.
45. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl. 1):122S-150S.
46. Kraeber-Bodéré F, Carlier T, Naegelen VM, et al. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med 2012; 53: 1836-1846.
47. 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res 2012; 18:6306-6314.
48. Jules Bordet Institute. HER2 imaging study to identify HER2 positive metastatic breast cancer patient unlikely to benefit from T-DM1 (ZEPHIR). Clinical Trials gov Identifier: NCT01565200.
49. Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol 2012; 30:4071-4076.
50. Baselga J, Cortés J, Kim SB, et al., CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-119.
51. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25-32.
52. Verma S, Miles D, Gianni L, et al., EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-1791.
53. Ibrahim YH, Garćia-Garćia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-1047.
54. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-365. doi: 10.1016/S0140-6736(12) 60868-X.
55. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703.
56. Choi YL, Soda M, Yamashita Y, et al., ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734-1739.
57. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500-504.
58. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.
59. Held MA, Langdon CG, Platt JT, et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 2013; 3:52-67.
60. Kreso A, O'Brien CA, van Galen P, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339:543-548.
61. Bachelot TD, Romieu G, Campone M, et al. LANDSCAPE: An FNCLCC phaseII study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011; 29(Suppl.; abstr 509).
62. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901.
63. Browman GP. Special series on comparative effectiveness research: chal lenges to real-world solutions to quality improvement in personalized medicine. J Clin Oncol 2012; 30:4188-4191.